# Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication

> **NCT04796584** · — · TERMINATED · sponsor: **Providence Health & Services** · enrollment: 20 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **OTHER:** Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus

## Key facts

- **NCT ID:** NCT04796584
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2022-07-11
- **Primary completion:** 2022-10-04
- **Final completion:** 2022-10-25
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Enrollment paused for greater than 6 months, data would not be relevant as enrollment took longer than expected.
- **Last updated:** 2023-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04796584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04796584, "Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT04796584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*